Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Bulletin Du Cancer|June 21, 2011
[EGFR/HER1: a target life]Erika Viel, Elsa Curtit, Laura Mansi, et al.
Future Oncology (London, England)|June 22, 2018
Milestones over the development of SB3, a trastuzumab biosimilarXavier Pivot, Igor Bondarenko, Thiery Petit, et al.
Expert Opinion on Investigational Drugs|June 8, 2026
Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor positive, HER2 negative metastatic breast cancerMarie Kroemer, Morgane Lopez, Laura Mansi, et al.
Bulletin Du Cancer|June 14, 2020
[Real-life study of 7-year survival in patients treated with trastuzumab for HER2+ early breast cancer]Mahasti Saghatchian, Elsa Curtit, David Coeffic, et al.
Bulletin Du Cancer|July 1, 2011
[Targeting the RAS signalling pathway in cancer]Laura Mansi, Erika Viel, Elsa Curtit, et al.
Cancers|June 27, 2024
Exercise Intervention on Insomnia in Patients with a Cancer: A Systematic Review of the LiteratureChloé Drozd, Elsa Curtit, Valérie Gillet, et al.
Cancers|November 13, 2025
Real-World Evidence of Long-Term Disease Control in HER2-Positive Metastatic Breast Cancer Patients Treated with a First-Line Combination of Trastuzumab and/or Pertuzumab Plus ChemotherapyLoïc Chaigneau, Eva Lapp, Taha Jai, et al.
Frontiers in Oncology|April 16, 2019
Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the LiteratureLouis Garnier, François Ducray, Clotilde Verlut, et al.
Frontiers in Oncology|July 10, 2023
Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysisElsa Curtit, Martine Marie Bellanger, Virginie Nerich, et al.
Medical Oncology (Northwood, London, England)|April 18, 2019
Interaction between phytotherapy and oral anticancer agents: prospective study and literature reviewAnne-Laure Clairet, Marie Boiteux-Jurain, Elsa Curtit, et al.
Pageof 5